AU2021337687A1 - Nectin-4 antibodies and uses thereof - Google Patents

Nectin-4 antibodies and uses thereof Download PDF

Info

Publication number
AU2021337687A1
AU2021337687A1 AU2021337687A AU2021337687A AU2021337687A1 AU 2021337687 A1 AU2021337687 A1 AU 2021337687A1 AU 2021337687 A AU2021337687 A AU 2021337687A AU 2021337687 A AU2021337687 A AU 2021337687A AU 2021337687 A1 AU2021337687 A1 AU 2021337687A1
Authority
AU
Australia
Prior art keywords
seq
nectin
antibody
antibodies
cdr1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021337687A
Other languages
English (en)
Inventor
Haichun Huang
Ming Lei
Han Li
Yi Pei
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSPC Megalith Biopharmaceutical Co Ltd
Original Assignee
CSPC Megalith Biopharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CSPC Megalith Biopharmaceutical Co Ltd filed Critical CSPC Megalith Biopharmaceutical Co Ltd
Publication of AU2021337687A1 publication Critical patent/AU2021337687A1/en
Assigned to CSPC Megalith Biopharmaceutical Co., Ltd., reassignment CSPC Megalith Biopharmaceutical Co., Ltd., Request for Assignment Assignors: NOVAROCK BIOTHERAPEUTICS, LTD.
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
AU2021337687A 2020-09-04 2021-09-03 Nectin-4 antibodies and uses thereof Pending AU2021337687A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063074864P 2020-09-04 2020-09-04
US63/074,864 2020-09-04
US202163166622P 2021-03-26 2021-03-26
US63/166,622 2021-03-26
PCT/US2021/049014 WO2022051591A2 (en) 2020-09-04 2021-09-03 Nectin-4 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
AU2021337687A1 true AU2021337687A1 (en) 2023-03-23

Family

ID=78080439

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021337687A Pending AU2021337687A1 (en) 2020-09-04 2021-09-03 Nectin-4 antibodies and uses thereof

Country Status (7)

Country Link
US (1) US20230331867A1 (cg-RX-API-DMAC7.html)
EP (1) EP4208259A2 (cg-RX-API-DMAC7.html)
JP (1) JP7851914B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230060509A (cg-RX-API-DMAC7.html)
AU (1) AU2021337687A1 (cg-RX-API-DMAC7.html)
CA (1) CA3193584A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022051591A2 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114845740B (zh) 2020-01-31 2026-06-02 先天制药公司 癌症的治疗
AU2021276616A1 (en) * 2020-05-20 2023-01-05 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4 and uses thereof
KR20240136924A (ko) * 2021-08-27 2024-09-19 씨에스피씨 메가리스 바이오파마슈티칼 씨오., 엘티디. 항 Nectin-4 항체, 약물 접합체 및 이의 제조방법 및 용도
CN116063498A (zh) * 2022-04-27 2023-05-05 博际生物医药科技(杭州)有限公司 单域抗Nectin-4抗体
WO2023227660A1 (en) * 2022-05-25 2023-11-30 Innate Pharma Nectin-4 binding agents
JP2025523049A (ja) * 2022-07-14 2025-07-17 バイオ-テラ ソリュ-ションズ,エルティーディー. 抗Nectin-4抗体及びその使用
CN117982672A (zh) * 2022-07-14 2024-05-07 百奥泰生物制药股份有限公司 抗Nectin-4抗体药物偶联物及应用
IL318911A (en) * 2022-09-20 2025-04-01 Nectin Therapeutics Ltd Humanized antibodies against NECTIN-4 and their drug conjugates
CN118871132A (zh) * 2023-02-27 2024-10-29 石药集团巨石生物制药有限公司 重组人源化抗Nectin-4单抗-MMAE偶联药物的药物组合物
JP7689606B2 (ja) * 2023-06-20 2025-06-06 イーライ リリー アンド カンパニー ネクチン-4抗体及び抗体-薬物コンジュゲート
KR20250177512A (ko) * 2024-06-14 2025-12-24 삼성바이오에피스 주식회사 신규한 항-넥틴-4 항체 및 이의 용도
US20260167719A1 (en) * 2024-12-17 2026-06-18 Merck Sharp & Dohme Llc Nectin-4 antibodies

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
AU7979491A (en) 1990-05-03 1991-11-27 Vical, Inc. Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
AU2235992A (en) 1991-06-14 1993-01-12 Genpharm International, Inc. Transgenic immunodeficient non-human animals
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
EP0593592B1 (en) 1991-07-08 1998-03-25 The University Of Massachusetts At Amherst Thermotropic liquid crystal segmented block copolymer
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1999029888A1 (en) 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
CN1399645A (zh) 1999-07-29 2003-02-26 米德列斯公司 Her2/neu的人单克隆抗体
US7271240B2 (en) 2001-03-14 2007-09-18 Agensys, Inc. 125P5C8: a tissue specific protein highly expressed in various cancers
US20040081653A1 (en) 2002-08-16 2004-04-29 Raitano Arthur B. Nucleic acids and corresponding proteins entitled 251P5G2 useful in treatment and detection of cancer
CN1961003B (zh) 2004-03-31 2013-03-27 健泰科生物技术公司 人源化抗TGF-β抗体
PE20090245A1 (es) 2007-05-08 2009-03-17 Genentech Inc Anticuerpos anti-muc16 disenados con cisteina y conjugados de anticuerpos y farmacos
BRPI0818780A2 (pt) 2007-10-19 2015-04-22 Genentech Inc Anticorpo anti-tenb2 planejados por cisteína e conjugados de medicamento com anticorpos
CA3220104A1 (en) 2010-06-08 2011-12-15 Genentech, Inc. Cysteine engineered antibodies and conjugates
ES2874306T3 (es) 2010-09-29 2021-11-04 Agensys Inc Conjugados de anticuerpos y fármacos (CAF) que se unen a las proteínas 191P4D12
CN102469482A (zh) 2010-11-12 2012-05-23 中兴通讯股份有限公司 一种广播控制信道信息倒换方法及系统
EP2729898A1 (en) 2011-07-10 2014-05-14 Blendology Limited An electronic data sharing device and method of use
WO2013063391A2 (en) 2011-10-28 2013-05-02 Trianni, Inc. Transgenic animals and methods of use
CA2858806A1 (en) 2011-12-23 2013-06-27 Innate Pharma Enzymatic conjugation of polypeptides
CN104640572B (zh) 2012-05-15 2018-04-27 索伦托医疗有限公司 药物偶联物,偶联方法,及其用途
US9738724B2 (en) 2012-06-08 2017-08-22 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
NO2789793T3 (cg-RX-API-DMAC7.html) 2012-10-24 2018-01-27
EP2916872B1 (en) 2012-11-09 2019-02-27 Innate Pharma Recognition tags for tgase-mediated conjugation
WO2014202773A1 (en) 2013-06-20 2014-12-24 Innate Pharma Enzymatic conjugation of polypeptides
KR20160042871A (ko) 2013-06-21 2016-04-20 이나뜨 파르마, 에스.아. 폴리펩티드의 효소적 콘쥬게이션
PL2845550T3 (pl) 2013-09-10 2017-08-31 Erbe Elektromedizin Gmbh Instrument chirurgiczny z trzonem z tworzywa sztucznego
CA2951887A1 (en) 2014-06-12 2015-12-17 Cspc Dophen Corporation Homogenous antibody drug conjugates via enzymatic methods
HUE049325T2 (hu) 2014-08-28 2020-09-28 Pfizer Stabilitás modulátor linker antitest-hatóanyag konjugátumokhoz történõ alkalmazásra
JP6817288B2 (ja) 2015-08-10 2021-01-20 ハンジョウ ディーエーシー バイオテック シーオー.,エルティディ.Hangzhou Dac Biotech Co.,Ltd. 新規な連結体及び生体分子と薬物との特異的共役におけるその使用
WO2017035252A1 (en) 2015-08-24 2017-03-02 Trianni, Inc. Enhanced production of immunoglobulins
EP3347048B1 (en) 2015-09-09 2020-04-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies having specificity to nectin-4 and uses thereof
CN108472386A (zh) 2015-10-02 2018-08-31 百时美施贵宝公司 用于缀合抗体的转谷氨酰胺酶变体
KR20190014525A (ko) 2016-05-27 2019-02-12 애브비 바이오테라퓨틱스 인크. 면역 조절 단백질과 종양 항원을 결합하는 이중특이적 결합 단백질
WO2018140590A1 (en) 2017-01-25 2018-08-02 Massachusetts Institute Of Technology Seft-labeling miniproteins and conjugates comprising them
US11274160B2 (en) 2017-03-02 2022-03-15 INSERM (Institut National de la Santé et de la Recherche Médicale Antibodies having specificity to Nectin-4 and uses thereof
KR20210125094A (ko) 2017-04-06 2021-10-15 항저우 디에이씨 바이오테크 씨오, 엘티디 비스-링키지를 사용한 세포독성 약물의 접합
TWI870338B (zh) 2017-06-05 2025-01-21 美商艾澤西公司 粘附分子-4結合蛋白及其使用方法
WO2019215782A1 (ja) 2018-05-07 2019-11-14 Hiyama Kazuhiro 診断情報提供装置、方法及びシステム
US12077583B2 (en) 2018-05-09 2024-09-03 Nectin Therapeutics Ltd. Antibodies specific to human NECTIN4

Also Published As

Publication number Publication date
US20230331867A1 (en) 2023-10-19
WO2022051591A2 (en) 2022-03-10
JP7851914B2 (ja) 2026-04-27
EP4208259A2 (en) 2023-07-12
JP2023540526A (ja) 2023-09-25
CA3193584A1 (en) 2022-03-10
KR20230060509A (ko) 2023-05-04
WO2022051591A3 (en) 2022-04-21

Similar Documents

Publication Publication Date Title
US20230331867A1 (en) Nectin-4 antibodies and uses thereof
US12460005B2 (en) Binding molecules specific for claudin 18.2, compositions and methods thereof, for treatment of cancer and other diseases
US20230272063A1 (en) Anti-claudin 18 antibodies and methods of use thereof
JP2024532485A (ja) Cd137および腫瘍関連抗原に結合する二重特異性結合タンパク質
US20250277026A1 (en) Antibodies against claudin-6 and uses thereof
AU2013369339B2 (en) Anti-LAMP1 antibodies and antibody drug conjugates, and uses thereof
KR20160097336A (ko) 신규 항-dpep3 항체 및 이의 사용 방법
KR20160070191A (ko) 신규한 항-클라우딘 항체 및 사용 방법
CN113382750A (zh) Cdcp1靶向疗法
US20220153863A1 (en) Prame binding molecules and uses thereof
KR20250152073A (ko) 항체, 항원 결합 단편 및 사용 방법
CN116507641A (zh) 结合素-4抗体及其用途
CN117597362A (zh) 抗紧密连接蛋白-6的抗体及其用途
US20260078179A1 (en) Cdh17 antibodies and uses thereof
HK40098610A (en) Nectin-4 antibodies and uses thereof
HK40107987A (en) Antibodies against claudin-6 and uses thereof
CN118165107A (zh) 结合tigit的抗体分子
CN118234511A (zh) 与cd137和肿瘤相关抗原结合的双特异性结合蛋白
HK40064186A (en) Anti-claudin 18 antibodies and methods of use thereof

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: CSPC MEGALITH BIOPHARMACEUTICAL CO., LTD.,

Free format text: FORMER APPLICANT(S): NOVAROCK BIOTHERAPEUTICS, LTD.